Eton Pharmaceuticals Files 8-K

TL;DR

Eton Pharma filed an 8-K, check for updates.

AI Summary

Eton Pharmaceuticals, Inc. filed an 8-K on March 22, 2024, to report other events and financial statements. The filing does not contain specific details about new events or financial figures within the provided text.

Why It Matters

This filing indicates Eton Pharmaceuticals is making a regulatory submission to the SEC, which could contain important updates for investors.

Risk Assessment

Risk Level: low — The filing is a standard procedural document without immediate disclosed negative or positive financial impacts.

Key Players & Entities

• Eton Pharmaceuticals, Inc. (company) — Registrant
• 20240322 (date) — Date of Report
• 001-38738 (company) — SEC File Number
• 37-1858472 (company) — I.R.S. Employer Identification Number
• 21925 W. Field Parkway , Suite 235 (location) — Principal executive offices address
• Deer Park (location) — City of principal executive offices
• Illinois (location) — State of principal executive offices
• 60010-7208 (location) — Zip code of principal executive offices
• ( 847 ) 787-7361 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.001 — h registered Common Stock , par value $0.001 per share ETON NASDAQ Global Market
• $2.2 million — the agreement, Eton will pay the seller $2.2 million for the acquisition and could pay up to
• $2 million — for the acquisition and could pay up to $2 million in additional commercial milestones, co
• $500,000 — cial milestones, consisting of one-time $500,000 payments when net sales in a year reach
• $4 m — payments when net sales in a year reach $4 million, $8 million, $15 million, and $20
• $8 m — n net sales in a year reach $4 million, $8 million, $15 million, and $20 million. Et
• $15 m — in a year reach $4 million, $8 million, $15 million, and $20 million. Eton will pay t
• $20 million — 4 million, $8 million, $15 million, and $20 million. Eton will pay the seller a royalty of

Filing Documents

• eton20240318_8k.htm (8-K) — 26KB
• ex_641459.htm (EX-99.1) — 19KB
• 0001437749-24-008919.txt ( ) — 181KB
• eton-20240322.xsd (EX-101.SCH) — 3KB
• eton-20240322_def.xml (EX-101.DEF) — 11KB
• eton-20240322_lab.xml (EX-101.LAB) — 15KB
• eton-20240322_pre.xml (EX-101.PRE) — 11KB
• eton20240318_8k_htm.xml (XML) — 3KB

01 Other Events

Item 8.01 Other Events. On March 22, 2024, Eton Pharmaceuticals, Inc. issued a press release announcing that it has entered into an agreement to acquire U.S. rights to PKU GOLIKE from Relief Therapeutics Holding SA ("Relief"). Under the terms of the agreement, Eton will pay the seller $2.2 million for the acquisition and could pay up to $2 million in additional commercial milestones, consisting of one-time $500,000 payments when net sales in a year reach $4 million, $8 million, $15 million, and $20 million. Eton will pay the seller a royalty of 30% of net sales, which will include the cost of the product. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits Exhibit 99.1 Press Release dated March 22, 202 4 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 22, 2024 By: /s/ James R. Gruber James R. Gruber Chief Financial Officer and Secretary (Principal Financial Officer) 3

View Full Filing

View this 8-K filing on SEC EDGAR